$27.82
0[0.00%]
At close: Apr 22
$27.82
0[0.00%]
PreMarket: 4:00PM EDT
Royalty Pharma
(NASDAQ:RPRX)Royalty Pharma Stock (NASDAQ:RPRX), Analyst Ratings, Price Targets, Predictions
Royalty Pharma PLC has a consensus price target of $49.33, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from B of A Securities, JP Morgan, and Goldman Sachs on April 12, 2024, February 20, 2024, and February 20, 2024. With an average price target of $43.33 between B of A Securities, JP Morgan, and Goldman Sachs, there's an implied 55.76% upside for Royalty Pharma PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
JP Morgan
Goldman Sachs
Morgan Stanley
Tigress Financial
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Royalty Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | RPRX | Buy Now | Royalty Pharma | $27.82 | 36.59% | B of A Securities | Geoff Meacham | $40 → $38 | Maintains | Buy | Get Alert |
| 02/20/2024 | RPRX | Buy Now | Royalty Pharma | $27.82 | 50.97% | JP Morgan | Chris Schott | $45 → $42 | Maintains | Overweight | Get Alert |
| 02/20/2024 | RPRX | Buy Now | Royalty Pharma | $27.82 | 79.73% | Goldman Sachs | Chris Shibutani | $56 → $50 | Maintains | Buy | Get Alert |
| 11/09/2023 | RPRX | Buy Now | Royalty Pharma | $27.82 | 104.89% | Morgan Stanley | Terence Flynn | $54 → $57 | Maintains | Overweight | Get Alert |
| 10/11/2023 | RPRX | Buy Now | Royalty Pharma | $27.82 | 94.1% | Morgan Stanley | Terence Flynn | $53 → $54 | Maintains | Overweight | Get Alert |
| 08/09/2023 | RPRX | Buy Now | Royalty Pharma | $27.82 | 90.51% | Morgan Stanley | Terence Flynn | $52 → $53 | Maintains | Overweight | Get Alert |
| 07/11/2023 | RPRX | Buy Now | Royalty Pharma | $27.82 | 86.92% | Morgan Stanley | Terence Flynn | $52 → $52 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2023 | RPRX | Buy Now | Royalty Pharma | $27.82 | 86.92% | Morgan Stanley | Terence Flynn | $50 → $52 | Maintains | Overweight | Get Alert |
| 04/10/2023 | RPRX | Buy Now | Royalty Pharma | $27.82 | 79.73% | Morgan Stanley | Terence Flynn | $48 → $50 | Maintains | Overweight | Get Alert |
| 04/06/2023 | RPRX | Buy Now | Royalty Pharma | $27.82 | 115.67% | Tigress Financial | Ivan Feinseth | $57 → $60 | Reiterates | → Buy | Get Alert |
| 02/16/2023 | RPRX | Buy Now | Royalty Pharma | $27.82 | 72.54% | UBS | Ashwani Verma | $51 → $48 | Maintains | Buy | Get Alert |
| 12/06/2022 | RPRX | Buy Now | Royalty Pharma | $27.82 | 83.32% | Morgan Stanley | Terence Flynn | $54 → $51 | Maintains | Overweight | Get Alert |
| 11/09/2022 | RPRX | Buy Now | Royalty Pharma | $27.82 | 94.1% | Morgan Stanley | Terence Flynn | $51 → $54 | Maintains | Overweight | Get Alert |
| 10/18/2022 | RPRX | Buy Now | Royalty Pharma | $27.82 | 86.92% | JP Morgan | Chris Schott | $50 → $52 | Maintains | Overweight | Get Alert |
| 08/08/2022 | RPRX | Buy Now | Royalty Pharma | $27.82 | 83.32% | Morgan Stanley | Terence Flynn | $48 → $51 | Maintains | Overweight | Get Alert |
| 07/14/2022 | RPRX | Buy Now | Royalty Pharma | $27.82 | 104.89% | Tigress Financial | Ivan Feinseth | $52 → $57 | Maintains | Buy | Get Alert |
| 06/14/2022 | RPRX | Buy Now | Royalty Pharma | $27.82 | 68.94% | UBS | Ashwani Verma | → $47 | Initiates | → Buy | Get Alert |
| 05/13/2022 | RPRX | Buy Now | Royalty Pharma | $27.82 | 90.51% | Scotiabank | Adam Buckham | → $53 | Initiates | → Outperform | Get Alert |
| 04/27/2022 | RPRX | Buy Now | Royalty Pharma | $27.82 | 101.29% | Goldman Sachs | Chris Shibutani | → $56 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Royalty Pharma (RPRX)?
The latest price target for Royalty Pharma (NASDAQ: RPRX) was reported by B of A Securities on April 12, 2024. The analyst firm set a price target for $38.00 expecting RPRX to rise to within 12 months (a possible 36.59% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Royalty Pharma (RPRX)?
The latest analyst rating for Royalty Pharma (NASDAQ: RPRX) was provided by B of A Securities, and Royalty Pharma maintained their buy rating.
When was the last upgrade for Royalty Pharma (RPRX)?
The last upgrade for Royalty Pharma PLC happened on April 14, 2022 when JP Morgan raised their price target to $50. JP Morgan previously had a neutral for Royalty Pharma PLC.
When was the last downgrade for Royalty Pharma (RPRX)?
There is no last downgrade for Royalty Pharma.
When is the next analyst rating going to be posted or updated for Royalty Pharma (RPRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating Royalty Pharma (RPRX) correct?
While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $40.00 to $38.00. The current price Royalty Pharma (RPRX) is trading at is $27.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.